{"id":62560,"date":"2026-01-29T07:06:00","date_gmt":"2026-01-29T06:06:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/"},"modified":"2026-01-29T07:06:00","modified_gmt":"2026-01-29T06:06:00","slug":"tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/","title":{"rendered":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122"},"content":{"rendered":"
\n

\nU.S. FDA Approves YUVEZZI\u2122 as the only dual-agent, once daily presbyopia-correcting eye drop<\/a><\/i><\/p>\n

LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and a credit facility.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe Company raised $85 million in Series B financing led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. Existing investors also participating include EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille. In addition to the Series B, Tenpoint entered into a $150 million non-dilutive senior secured term loan facility with Hercules Capital.<\/p>\n

\n\u201cWe deeply appreciate the support of our strong syndicate of global, long-term investors. This financing reflects their confidence in YUVEZZI, a new differentiated option for millions of people living with the daily frustration and challenges of presbyopia,\u201d said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. \u201cWith our strengthened balance sheet, we are excited to launch YUVEZZI in early Q2.\u201d<\/p>\n

\n\u201cIt\u2019s incredibly exciting to see the Series B financing and YUVEZZI approval align at the same moment, creating the perfect launch point for this exceptional ophthalmology team to deliver a best-in-class dual agent to this massive market,\u201d said David Guyer M.D., Chairman of Tenpoint Therapeutics.<\/p>\n

\n\u201cYUVEZZI\u2019s differentiated favorable safety and tolerability profile reinforces our confidence in its commercial potential to resonate with patients and providers as Tenpoint drives towards its successful launch,\u201d said Agustin Mohedas, Ph.D., Portfolio Manager & Research Analyst at Janus Henderson Investors. \u201cWith extensive ophthalmology experience, Tenpoint\u2019s leadership team has executed key milestones toward commercialization and is well positioned to bring this differentiated new treatment to the presbyopia market.\u201d<\/p>\n

\nAbout Tenpoint Therapeutics<\/b><\/p>\n

\nTenpoint Therapeutics Ltd. is a global biotechnology company focused on the commercialization of YUVEZZI\u2122 (carbachol and brimonidine tartrate ophthalmic solution) 2.75% \/ 0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally. By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.<\/p>\n

\nTo learn more, visit tenpointtherapeutics.com<\/a> and connect on LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:
\n
Ami Bavishi or Nick Colangelo
\n
tenpoint@gilmartinir.com<\/a><\/p>\n

\nMedia:
\n
Brandi Robinson
\n
media@tenpointtx.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

U.S. FDA Approves YUVEZZI\u2122 as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62560","6":"format-standard","7":"category-industry"},"yoast_head":"\nTenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"U.S. FDA Approves YUVEZZI\u2122 as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T06:06:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122\",\"datePublished\":\"2026-01-29T06:06:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/\"},\"wordCount\":410,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128574430\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/\",\"name\":\"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128574430\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"datePublished\":\"2026-01-29T06:06:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128574430\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260128574430\\\/en\\\/2632462\\\/22\\\/Tenpoint_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/","og_locale":"en_US","og_type":"article","og_title":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend","og_description":"U.S. FDA Approves YUVEZZI\u2122 as the only dual-agent, once daily presbyopia-correcting eye drop LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-29T06:06:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122","datePublished":"2026-01-29T06:06:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/"},"wordCount":410,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/","url":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/","name":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","datePublished":"2026-01-29T06:06:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260128574430\/en\/2632462\/22\/Tenpoint_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tenpoint-therapeutics-secures-235-million-through-series-b-stock-financing-and-credit-facility-to-accelerate-commercialization-of-yuvezzi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI\u2122"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62560"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62560\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}